Taysha Gene Therapies
Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations
Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced that it has closed an oversubscribed $95 million Series B financing with a premier syndicate of life science investors, led by Fidelity Management & Research ...
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A financing round.
Scientific first: RNA repair shows promise in reversing mutations underlying a neurological disorder
OHSU study first to use programmable RNA editing to repair gene that contributes to Rett syndrome.
The coronavirus pandemic has stretched hospital resources beyond their capacity, disrupted the delivery of care, and drained providers of billions of dollars of revenue for canceled elective procedures, office visits, and tests.
The world's largest brain research prize is Danish and is awarded by the Lundbeck Foundation. Each year, we award 10 million DKK (approx. 1,3 million€) to one or more brain researchers who have had a ground-breaking impact on brain research.
When X-linked genes evade silencing on the “inactive” chromosome in XX cells, some protect women from diseases such as cancer, but others seem to promote conditions such as autoimmunity.
Gene or genome editing describes a process by which targeted and deliberate changes to the DNA sequence are made. Recent advances in programmable nucleases, including the CRISPR-Cas9 system, mean that manipulating DNA has never been easier, which could fundamentally alter the way we treat and ...
Making changes to the molecular messengers that create proteins might offer flexible therapies for cancer, pain or high cholesterol, in addition to genetic disorders.
Austrian pediatrician Andreas Rett first recognized the syndrome that would later bear his name in the mid-1960s. The first description in English, published in 1983, detailed a “progressive syndrome of autism” and other traits in 35 girls.